Vascepa cuts risk of potentially fatal CV events in at-risk patients after procedure

A post hoc sub-analysis of the REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), has found that Vascepa (icosapent ethyl) significantly cut the risk of cardiovascular (CV) death, strokes, heart attacks, coronary revascularization, and unstable angina by 34% in those with a history of percutaneous coronary intervention (PCI).

The REDUCE-IT PCI subgroup analysis was funded by fish-oil based CV specialist Amarin (Nasdaq: AMRN), the company behind Vascepa, a drug also branded as Vazkepa which is the only prescription treatment approved by the US Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid.

"Additional evidence that our product can be a vital contributor in reducing harm and deaths from CV disease around the world"Deepak Bhatt, executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, is the principal investigator of REDUCE-IT and senior author of the REDUCE-IT Prior PCI analyses.